$OTLK
Outlook Therapeutics, Inc.

2022 Q4 Form 10-K Financial Statement

#000155837022019036 Filed on December 29, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.826M $4.998M $20.74M
YoY Change 77.76% 42.77% 62.43%
% of Gross Profit
Research & Development $9.862M $8.990M $42.33M
YoY Change -0.1% -9.51% 8.66%
% of Gross Profit
Depreciation & Amortization $10.78K $51.47K $163.6K
YoY Change -73.65% 1.58% 0.0%
% of Gross Profit
Operating Expenses $9.862M $13.99M $42.33M
YoY Change -0.1% 4.11% -18.16%
Operating Profit -$15.69M -$63.07M
YoY Change 19.3% 21.93%
Interest Expense -$2.427M -$367.0K -$1.536M
YoY Change 546.89% -406.27% 56.34%
% of Operating Profit
Other Income/Expense, Net $30.26K $11.00K -$417.0K
YoY Change -65.43% -112.41% -7.77%
Pretax Income -$18.66M -$14.34M -$66.05M
YoY Change 29.04% 7.01% 24.24%
Income Tax $1.000K $2.800K
% Of Pretax Income
Net Earnings -$18.66M -$14.35M -$66.05M
YoY Change 29.04% 7.02% 24.24%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.31
Diluted Earnings Per Share -$0.08 -$64.91K -$0.31
COMMON SHARES
Basic Shares Outstanding 228.2M 226.1M 212.1M
Diluted Shares Outstanding 227.4M 212.1M

Balance Sheet

Concept 2022 Q4 2022 Q3 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.34M $17.40M $17.40M
YoY Change -25.39% 20.17% 20.17%
Cash & Equivalents $52.34M $17.40M
Short-Term Investments
Other Short-Term Assets $9.335M $10.12M $10.12M
YoY Change 27.59% 43.99% 43.99%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $61.68M $27.52M $27.52M
YoY Change -20.38% 27.95% 27.95%
LONG-TERM ASSETS
Property, Plant & Equipment $59.58K $70.36K $70.36K
YoY Change -51.45% -57.0% -74.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $826.4K $804.9K $804.9K
YoY Change -0.43% -5.71% -5.71%
Other Assets $126.4K $132.0K $132.0K
YoY Change -19.31% -24.39% -24.38%
Total Long-Term Assets $1.012M $1.007M $1.007M
YoY Change -16.39% -22.71% -22.71%
TOTAL ASSETS
Total Short-Term Assets $61.68M $27.52M $27.52M
Total Long-Term Assets $1.012M $1.007M $1.007M
Total Assets $62.69M $28.53M $28.53M
YoY Change -20.32% 25.06% 25.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.170M $3.491M $3.491M
YoY Change 63.81% 58.97% 58.97%
Accrued Expenses $9.028M $3.428M $3.455M
YoY Change 226.66% 98.64% 95.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $12.14K $10.93M $10.93M
YoY Change -99.9% 1074.09% 1074.09%
Total Short-Term Liabilities $15.08M $19.73M $19.73M
YoY Change -24.4% 192.2% 192.2%
LONG-TERM LIABILITIES
Long-Term Debt $31.82M $4.270K $4.270K
YoY Change 230.86% -99.96% -99.96%
Other Long-Term Liabilities $26.88K $57.14K $57.14K
YoY Change -90.69% -89.61% -89.61%
Total Long-Term Liabilities $31.85M $61.41K $61.41K
YoY Change 221.5% -99.46% -99.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.08M $19.73M $19.73M
Total Long-Term Liabilities $31.85M $61.41K $61.41K
Total Liabilities $46.93M $19.79M $19.79M
YoY Change 57.19% 8.72% 8.72%
SHAREHOLDERS EQUITY
Retained Earnings -$427.6M -$408.9M
YoY Change 19.66% 19.25%
Common Stock $443.4M $417.7M
YoY Change 9.16% 20.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.76M $8.737M $8.737M
YoY Change
Total Liabilities & Shareholders Equity $62.69M $28.53M $28.53M
YoY Change -20.32% 25.06% 25.06%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022
OPERATING ACTIVITIES
Net Income -$18.66M -$14.35M -$66.05M
YoY Change 29.04% 7.02% 24.24%
Depreciation, Depletion And Amortization $10.78K $51.47K $163.6K
YoY Change -73.65% 1.58% 0.0%
Cash From Operating Activities -$8.901M -$10.25M -$56.67M
YoY Change -19.01% 14.02% 4.46%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $62.31M
YoY Change 34.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.85M 1.626M 59.59M
YoY Change -34.23% -56.93% 6.05%
NET CHANGE
Cash From Operating Activities -8.901M -10.25M -56.67M
Cash From Investing Activities
Cash From Financing Activities 43.85M 1.626M 59.59M
Net Change In Cash 34.94M -8.625M 2.919M
YoY Change -37.23% 65.39% 50.39%
FREE CASH FLOW
Cash From Operating Activities -$8.901M -$10.25M -$56.67M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants http://www.outlooktherapeutics.com/20220930#ChangeInFairValueOfRedemptionFeature
CY2022 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2022#FairValueAdjustmentOfWarrants http://www.outlooktherapeutics.com/20220930#ChangeInFairValueOfRedemptionFeature
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001649989
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
227310572
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
176461628
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212079472
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152676145
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
212079472
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152676145
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37759
CY2022 dei Entity Registrant Name
EntityRegistrantName
OUTLOOK THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
38-3982704
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
485 Route 1 South
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Building F, Suite 320
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Iselin
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08852
CY2022 dei City Area Code
CityAreaCode
609
CY2022 dei Local Phone Number
LocalPhoneNumber
619-3990
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
OTLK
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 dei Entity Public Float
EntityPublicFloat
221500000
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
228205963
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17396812
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14477324
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10123634
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7030823
CY2022Q3 us-gaap Assets Current
AssetsCurrent
27520446
CY2021Q3 us-gaap Assets Current
AssetsCurrent
21508147
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163625
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70360
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111429
CY2022Q3 us-gaap Equity Method Investments
EquityMethodInvestments
804930
CY2021Q3 us-gaap Equity Method Investments
EquityMethodInvestments
853660
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
132015
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
174590
CY2022Q3 us-gaap Assets
Assets
28527751
CY2021Q3 us-gaap Assets
Assets
22811451
CY2022Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
10915015
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
904200
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
11751
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
26464
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
26995
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
42854
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3491485
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2196349
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3427900
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1725721
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1856629
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19729775
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6752217
CY2021Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
10885854
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4267
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
16018
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26995
CY2022Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
57138
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
522918
CY2022Q3 us-gaap Liabilities
Liabilities
19791180
CY2021Q3 us-gaap Liabilities
Liabilities
18204002
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7300000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
227310572
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
176461628
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
2273105
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1764616
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
415398984
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345726087
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408935518
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-342883254
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8736571
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28527751
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22811451
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42330856
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38958010
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20739897
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12768725
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-63070753
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-51726735
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-48730
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-46340
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1487456
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-936127
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
CY2022 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
882903
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-465780
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
452146
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66049464
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53161348
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2800
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66052264
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53163348
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
212079472
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152676145
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2826291
CY2021 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
3593380
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46463839
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4887287
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-53163348
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
4607449
CY2022 otlk Stock Issue During Period Value In Connection With Exercise Of Warrants
StockIssueDuringPeriodValueInConnectionWithExerciseOfWarrants
188100
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17750
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
62264732
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7710804
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-66052264
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8736571
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-66052264
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-53163348
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
204694
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
262140
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1025402
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
1655340
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
893886
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
7710804
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4887287
CY2022 otlk Change In Fair Value Of Redemption Feature
ChangeInFairValueOfRedemptionFeature
882903
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-465780
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
452146
CY2021 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
552340
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-48730
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-46340
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3092811
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1729944
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-298523
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-42854
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-150346
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1295136
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-198469
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
156141
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5299163
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56674559
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54253288
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
62307307
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46301841
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
8032
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
188100
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3593380
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17750
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26464
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
29778
CY2021 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
3612500
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
12292646
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
50285
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
600000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59594047
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
56194626
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2919488
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1941338
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14477324
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12535986
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17396812
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14477324
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1556691
CY2021 us-gaap Interest Paid Net
InterestPaidNet
46239
CY2022 otlk Amortization Of Deferred Offering Cost
AmortizationOfDeferredOfferingCost
42575
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
16018
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.     Organization and Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Outlook Therapeutics, Inc. (“Outlook” or the “Company”) was incorporated in New Jersey on January 5, 2010, started operations in July 2011, reincorporated in Delaware by merging with and into a Delaware corporation in October 2015 and changed its name to “Outlook Therapeutics, Inc.” in November 2018. The Company is a biopharmaceutical company focused on developing and commercializing ONS-5010, an ophthalmic formulation of bevacizumab for use in retinal indications. The Company is based in Iselin, New Jersey. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has been actively monitoring the COVID-19 pandemic and its impact globally. Given the Company’s current infrastructure needs and current strategy, the Company was able to transition to remote working with limited impact on productivity, as shelter-in-place and similar government orders were imposed. All development activities are currently active in support of the Company’s Biologics License Application (“BLA”) registration program for ONS-5010 for wet age-related macular degeneration (“wet AMD”). In fiscal year 2022, the Company submitted the BLA and received confirmation from the U.S. Food and Drug Administration (“FDA”) that the BLA had been accepted for filing with a goal date of August 29, 2023 for a review decision by the FDA. Additionally, the Company submitted a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA), which has been validated for review with an estimated decision date expected in early 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19. Management believes the financial results for the year ended September 30, 2022 were not significantly impacted by COVID-19.</p>
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-408900000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3427900
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1725721
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2021 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p>
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3141
CY2021 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5093
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2021Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
100000
CY2022Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
0
CY2022 otlk Finance Lease Cost
FinanceLeaseCost
3141
CY2021 otlk Finance Lease Cost
FinanceLeaseCost
5093
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
44867
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
106879
CY2022 us-gaap Lease Cost
LeaseCost
48008
CY2021 us-gaap Lease Cost
LeaseCost
111972
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
70360
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111429
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
26995
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
69849
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067351
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1067351
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1067351
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
903726
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163625
CY2022 us-gaap Depreciation
Depreciation
163625
CY2021 us-gaap Depreciation
Depreciation
163624
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1976252
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
753808
CY2022Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
744154
CY2021Q3 otlk Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
808780
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
12909
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
564423
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
143071
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
150224
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11114518
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
11842345
CY2022Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
199503
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
52291
CY2022Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
10915015
CY2021Q3 us-gaap Notes And Loans Payable
NotesAndLoansPayable
11790054
CY2022Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
10915015
CY2021Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
904200
CY2021Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
10885854
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11114518
CY2020Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3000000
CY2021Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
625000
CY2022Q2 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
750000
CY2022Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
42482
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2021Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M12D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.075
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.130
CY2021Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.095
CY2022 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
3141
CY2021 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
5093
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
46652
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
158708
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
26464
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
29778
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
128473
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
27675
CY2022Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
13149
CY2022Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
4383
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27675
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
17532
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
680
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
1514
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
26995
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
16018
CY2022 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
1
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
1
CY2022 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.03
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
83266
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
40305
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
325000000
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
77318
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6812794
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7710804
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4887287
CY2020Q1 otlk Number Of Executive Officers
NumberOfExecutiveOfficers
2
CY2021Q3 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
45995
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2800
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1856629
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.071
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.070
CY2021 otlk Effective Income Tax Rate Reconciliation Net Operating Losses Percent
EffectiveIncomeTaxRateReconciliationNetOperatingLossesPercent
0.019
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.004
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.035
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.037
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.321
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.307
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.013
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
83971779
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67778970
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4331889
CY2021Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2168228
CY2022Q3 otlk Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
7588
CY2021Q3 otlk Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
31577
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11166153
CY2021Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8842001
CY2022Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
2357309
CY2021Q3 us-gaap Deferred Tax Assets Tax Credit Carryforwards Foreign
DeferredTaxAssetsTaxCreditCarryforwardsForeign
2357309
CY2022Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
815310
CY2021Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
348605
CY2022Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
102650028
CY2021Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
81526690
CY2022Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
102630250
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
81449372
CY2022Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
19778
CY2022Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
19778
CY2021Q3 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
31323
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
21200000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16300000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.243
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210

Files In Submission

Name View Source Status
0001558370-22-019036-index-headers.html Edgar Link pending
0001558370-22-019036-index.html Edgar Link pending
0001558370-22-019036.txt Edgar Link pending
0001558370-22-019036-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
otlk-20220930.xsd Edgar Link pending
otlk-20220930x10k.htm Edgar Link pending
otlk-20220930x10k006.jpg Edgar Link pending
otlk-20220930x10k007.jpg Edgar Link pending
otlk-20220930x10k008.jpg Edgar Link pending
otlk-20220930xex10d38.htm Edgar Link pending
otlk-20220930xex21d1.htm Edgar Link pending
otlk-20220930xex23d1.htm Edgar Link pending
otlk-20220930xex31d1.htm Edgar Link pending
otlk-20220930xex31d2.htm Edgar Link pending
otlk-20220930xex32d1.htm Edgar Link pending
otlk-20220930xex4d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
otlk-20220930_def.xml Edgar Link unprocessable
otlk-20220930_pre.xml Edgar Link unprocessable
otlk-20220930_lab.xml Edgar Link unprocessable
otlk-20220930x10k_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
otlk-20220930_cal.xml Edgar Link unprocessable